OptiNose (OPTN)

Name: OptiNose (OPTN) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: OptiNose (OPTN)

Stock Card

$9.60

$0.00 (0.00%)

As on 21-May-2025 09:30EDT

Market cap

$97 Mln

Revenue (TTM)

$82 Mln

P/E Ratio

P/B Ratio

24.3

Div. Yield

0 %

OptiNose (OPTN) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 9.60 High: 9.60

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-10.5 %
ROCE

-- %
Industry P/E

37.32
EV/EBITDA

-4.3
Debt to Equity

0
Book Value

$--
EPS

$-2.1
Face value

--
Shares outstanding

10,127,400

9 Years Aggregate

CFO

$-476.60 Mln

EBITDA

$-472.90 Mln

Net Profit

$-562.06 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
OptiNose (OPTN)	43.7	4.7	60.0	-46.7	-30.9	-31.9	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 21-May-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
OptiNose (OPTN)	-65.2	-30.3	14.2	-60.9	-55.1	48.7	-67.0
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About OptiNose (OPTN)

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary... exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc. Read more

CEO & Director

Dr. Ramy A. Mahmoud M.D., M.P.H.
CEO & Director

Dr. Ramy A. Mahmoud M.D., M.P.H.
Headquarters

Yardley, PA
Website

https://www.optinose.com

FAQs for OptiNose (OPTN)

What is the current share price of OptiNose (OPTN) Today?

The share price of OptiNose (OPTN) is $9.60 (NASDAQ) as of 21-May-2025 09:30 EDT. OptiNose (OPTN) has given a return of -30.9% in the last 3 years.

What is the current PB & PE ratio of OptiNose (OPTN)?

Since, TTM earnings of OptiNose (OPTN) is negative, P/E ratio is not available.
The P/B ratio of OptiNose (OPTN) is 24.26 times as on 21-May-2025, a 213 premium to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.